MARK4 aggravates cardiac dysfunction in mice with STZ-induced diabetic cardiomyopathy by regulating ACSL4-mediated myocardial lipid metabolism

Yi Wu,Jingqi Zhang,Weiyi Wang,Dongdong Wu,Yang Kang,Lu Fu

DOI: https://doi.org/10.1038/s41598-024-64006-7

IF: 4.6

2024-06-07

Scientific Reports

Abstract:Diabetic cardiomyopathy is a specific type of cardiomyopathy. In DCM, glucose uptake and utilization are impaired due to insulin deficiency or resistance, and the heart relies more heavily on fatty acid oxidation for energy, resulting in myocardial lipid toxicity-related injury. MARK4 is a member of the AMPK-related kinase family, and improves ischaemic heart failure through microtubule detyrosination. However, the role of MARK4 in cardiac regulation of metabolism is unclear. In this study, after successful establishment of a diabetic cardiomyopathy model induced by streptozotocin and a high-fat diet, MARK4 expression was found to be significantly increased in STZ-induced DCM mice. After AAV9-shMARK4 was administered through the tail vein, decreased expression of MARK4 alleviated diabetic myocardial damage, reduced oxidative stress and apoptosis, and facilitated cardiomyocyte mitochondrial fusion, and promoted myocardial lipid oxidation metabolism. In addition, through the RNA-seq analysis of differentially expressed genes, we found that MARK4 deficiency promoted lipid decomposition and oxidative metabolism by downregulating the expression of ACSL4, thus reducing myocardial lipid accumulation in the STZ-induced DCM model.

multidisciplinary sciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role and mechanism of microtubule - affinity - regulating kinase 4 (MARK4) in cardiac dysfunction in a streptozotocin (STZ) - induced diabetic cardiomyopathy (DCM) mouse model. Specifically, the study aims to reveal the following points:

1. **Expression changes of MARK4 in DCM**: By detecting the expression level of MARK4 in the STZ - induced DCM mouse model, determine whether it changes during the disease process.

2. **Effect of MARK4 on cardiac function**: By knocking down MARK4 expression, observe its effect on cardiac function, oxidative stress, cardiomyocyte apoptosis and myocardial lipid metabolism in STZ - induced DCM mice.

3. **Relationship between MARK4 and ACSL4**: Through RNA - sequencing analysis, explore how MARK4 affects myocardial lipid metabolism by regulating the expression of ACSL4 (long - chain acyl - CoA synthetase 4).

### Main findings

- **Up - regulation of MARK4 expression**: In the STZ - induced DCM mouse model, the expression of MARK4 is significantly increased.
- **Knockdown of MARK4 improves cardiac function**: By injecting AAV9 - shMARK4 via the tail vein to reduce MARK4 expression, myocardial injury can be alleviated, oxidative stress and apoptosis can be reduced, myocardial mitochondrial fusion can be promoted, and myocardial lipid oxidative metabolism can be promoted.
- **MARK4 regulates lipid metabolism through ACSL4**: RNA - sequencing analysis shows that knockdown of MARK4 promotes lipid decomposition and oxidative metabolism and reduces myocardial lipid accumulation by down - regulating the expression of ACSL4.

### Conclusion

This study is the first to prove that MARK4 is up - regulated in the STZ - induced DCM mouse model, and by knocking down MARK4 expression, cardiac function can be improved, oxidative stress and cardiomyocyte apoptosis can be alleviated, and myocardial lipid oxidative metabolism can be promoted. These results suggest that MARK4 may become an effective target for the treatment of diabetic cardiomyopathy.